•Signaling by FGFR3 fusions in cancer (HSA-8853334)•Signaling by PDGFRA transmembrane, juxta- membrane, and kinase domain mutants (HSA-9673767)•Activated NTRK2 signals through RAS (HSA-9026519) Signaling by FGFR4 in disease (HSA-5655291)•Constitutive signaling by overexpressed ERBB2 (HSA-9634285) Constitutive signaling by EGFRvIII (HSA- 5637810)•MET activates PI3K/AKT signaling (HSA- 8851907). This evidence concerns the gene FGFR4 and cancer.